Skip Navigation


CIT can broadcast your seminar, conference or meeting live to a world-wide audience over the Internet as a real-time streaming video. The event can be recorded and made available for viewers to watch at their convenience as an on-demand video or a downloadable podcast. CIT can also broadcast NIH-only or HHS-only content.

Quantitative Biology and Biomarker Discovery without Immunoassays

Loading video...

 
   
Air date: Wednesday, March 30, 2011, 3:00:00 PM
Time displayed is Eastern Time, Washington DC Local
Views: Total views: 331 * This only includes stats from October 2011 and forward.
Category: WALS - Wednesday Afternoon Lectures
Runtime: 01:02:48
Description: Lack of antibody reagents and robust quantitative methods with sufficient sensitivity, specificity, reproducibility and throughput has significantly hampered our ability to understand dynamic, protein-based biological processes. This deficiency been particularly acute in the area of disease biomarkers where the lack of methods to assay for the presence and level of large (100’s) numbers of minimally credentialed candidate biomarker proteins in patient samples has stymied the introduction of new protein biomarkers into clinical use. My laboratory is addressing this serious barrier by developing targeted mass spectrometry-based technologies to screen and quantify low abundance proteins in a variety of biological contexts including human plasma.

The methods we have developed enable construction of highly multiplexed (>100plex), sensitive (10’s of copies/cell and <1 ng/mL in blood) assays with near clinical-grade performance for nearly any protein of interest. MS-based assays can also be generically constructed to measure many modifications, mutations and splice variants. We are applying these quantitative approaches in the context of a generalizable proteomics-based discovery-through-verification pipeline to identify early biomarkers of cardiovascular injury, breast cancer and infectious disease. These studies are beginning to demonstrate that modern proteomic technologies when coherently integrated can yield novel, credentialed protein biomarker candidates of sufficient merit to warrant real clinical evaluation.

The NIH Wednesday Afternoon Lecture Series includes weekly scientific talks by some of the top researchers in the biomedical sciences worldwide.

For more information, visit:
http://wals.od.nih.gov/
Debug: Show Debug
NLM Title: Quantitative biology and biomarker discovery without immunoassays [electronic resource] / Steven Carr.
Author: Carr, S A.
National Institutes of Health (U.S.)
Publisher:
Abstract: (CIT): Lack of antibody reagents and robust quantitative methods with sufficient sensitivity, specificity, reproducibility and throughput has significantly hampered our ability to understand dynamic, protein-based biological processes. This deficiency been particularly acute in the area of disease biomarkers where the lack of methods to assay for the presence and level of large (100"s) numbers of minimally credentialed candidate biomarker proteins in patient samples has stymied the introduction of new protein biomarkers into clinical use. My laboratory is addressing this serious barrier by developing targeted mass spectrometry-based technologies to screen and quantify low abundance proteins in a variety of biological contexts including human plasma. The methods we have developed enable construction of highly multiplexed (>100plex), sensitive (10"s of copies/cell and <1 ng/mL in blood) assays with near clinical-grade performance for nearly any protein of interest. MS-based assays can also be generically constructed to measure many modifications, mutations and splice variants. We are applying these quantitative approaches in the context of a generalizable proteomics-based discovery-through-verification pipeline to identify early biomarkers of cardiovascular injury, breast cancer and infectious disease. These studies are beginning to demonstrate that modern proteomic technologies when coherently integrated can yield novel, credentialed protein biomarker candidates of sufficient merit to warrant real clinical evaluation.
Subjects: Biomarkers--analysis
Mass Spectrometry--methods
Protein Array Analysis
Proteins--analysis
Proteomics--methods
Publication Types: Lectures
Webcasts
Download: To download this event, select one of the available bitrates:
[256k]  [512k]    How to download a Videocast
Caption Text: Download Caption File
NLM Classification: QW 541
NLM ID: 101559820
CIT Live ID: 10106
Permanent link: https://videocast.nih.gov/launch.asp?16559

 

Podcast information
Audio Podcasts   Video Podcasts
  Description Runtime     Description Runtime
Listen to the podcast Audio Podcast 1:02:48   Watch the podcast Video Podcast 1:02:48